GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

August 09, 2017

Reduction in total cholesterol levels from 196.5 mg/dL at baseline to 161.0 mg/dL (p = <0.0001) Reduction in diastolic blood pressure from 84.8 mmHg at baseline to 71.2 mmHg>

Notably, data from a subset of six patients with type 2 diabetes with mean baseline HbA1c of 7.9% showed that patients achieved a mean reduction in HbA1c of 1.4>

"At a time when physicians are seeking alternatives to pharmaceutical and surgical interventions for obesity and type 2 diabetes, these 12-month data are further support for the market potential of EndoBarrier and pave the way for our upcoming launch of EndoBarrier in Europe this fall," said Stuart A. Randle, chief executive officer of GI Dynamics. "We believe that our breakthrough non-surgical therapeutic has the potential to change the treatment paradigm for obese patients who want to regain control of their type 2 diabetes while also potentially improving other factors associated with these conditions."

In addition, EndoBarrier data was highlighted at IFSO in the Latin American Course by Dr. Escalona and the "Innovations in Endoluminal Procedures" session by Jan Willem Greve, M.D., Ph.D., Gastrointestinal and Bariatric Surgery, Atrium Medical Center Parkstad, Heerlen, Netherlands and member of GI Dynamics' scientific advisory board, which took place on Saturday, September 4, 2010.

Source : GI Dynamics